| Aug 13 |
Acumen Pharmaceuticals GAAP EPS of -$0.34 misses by $0.05
|
| Aug 13 |
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
|
| Aug 6 |
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
|
| Jul 30 |
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
|
| Jul 29 |
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
|
| Jul 28 |
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
| Jul 11 |
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
| Jun 21 |
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?
|
